Patients With Treatment-Naïve CLL Treated With BTK Inhibition

Reviewing Long-Term CLL Treatment With BTK Inhibitor Zanubrutinib

During a live event, Mazyar Shadman, MD, MPH, discussed zanubrutinib’s long-term outcomes in CLL for high-risk patients.

Choosing First-Line CLL Therapy in a Patient With Del(17p), TP53

During a live event, Mazyar Shadman, MD, MPH, discussed options for a patient with high-risk CLL as recommended by the NCCN guidelines.

Oncologists Weigh Pros and Cons of Dual Oral Therapy in CLL

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal patient selection for CLL.

Oncologists Weigh Pros and Cons of Dual Oral Therapy in CLL

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal patient selection for CLL.

Tailoring CLL Treatment with BTK Inhibitors in a Community Setting

During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences when choosing CLL treatment.

Exploring BTK Inhibitors for Patients With CLL and Del(17p) Mutations

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

Incorporating MRD Into Monitoring After Fixed-Duration CLL Treatment

During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD following fixed-duration treatment of chronic lymphocytic leukemia.

Newer Fixed Duration and Continuous Regimens Change Practice in CLL

During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax might be used in patients with chronic lymphocytic leukemia.

Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.

Deciding on Therapy for a Patient With High-Risk Relapsed CLL

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic lymphocytic leukemia who received 1 prior line of therapy in the first article of a 2-part series.

Subgroup and Toxicity Analyses Favor Zanubrutinib Vs Ibrutinib in CLL

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed subgroup analyses and adverse events from the ALPINE trial of zanubrutinib for a patient with relapsed/refractory chronic lymphocytic leukemia in the second article of a 2-part series.

Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.

Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL

During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.

Hoffmann Discusses Deciding Factors for Treating Patients With CLL

In the first article of a 2-part series, Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of treatment in patients with chronic lymphocytic leukemia.

Managing Cardiac Toxicities with Zanubrutinib in Relapsed CLL

In the second article of a 2-part series, Sameer A. Parikh, MBBS, looks at the risk of cardiac related toxicities with zanubrutinib for patients with relapsed chronic lymphocytic leukemia.

ALPINE Trial Data Shows Effectiveness of Zanubrutinib in Relapsed CLL

In the first article of a 2-part series, Sameer A. Parikh, MBBS, discusses the makeup and design of the phase 3 ALPINE study that showed the promise for the next-generation Bruton tyrosine kinase inhibitor zanubrutinib.

Second Generation BTK Inhibitors Improve Survival in R/R CLL Setting

In the second article of a 2-part series, William G. Wierda, MD, PhD, looks at the efficacy and safety outcomes with the second generation BTK inhibitor zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

Fitting Second Generation BTK Inhibitors into the R/R CLL Setting

In the first article of a 2-part series, William G. Wierda, MD, PhD, discusses the role Bruton tyrosine kinase inhibitors play in the relapsed/refractory chronic lymphocytic leukemia setting.